🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#Antibiotics are life-saving medicines that may come at a harmful cost. Abx disrupt your #microbiome like a fire in the forest, wiping out both good and bad #bacteria says This is not the CDC. Learn more about the harmful effects of antibiotics here: bit.ly/CDC_AR #WorldMicrobiomeDay

Synthetic Biologics’ VP of Non-Clinical Affairs and VP of Research both present today at #Anaerobe 2018 in Las Vegas on preventing #Cdiff infection and #AntimicrobialResistance. #AMR #CDI #Microbiome

Hitting the conference circuit this fall? Connect with the Synthetic Biologic’s team at one of these upcoming events. To see the full list of upcoming conferences and seminars we’re attending, visit our website at bit.ly/synevents. #microbiome #IBS #CDI #Cdiff #AMR

We are looking forward to joining the C DIFF FOUNDATION at #Cdiff18 this November - Register to reserve your spot at cdifffoundation.org/registration/

Steven Shallcross, Interim CEO and CFO, to present at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, in NYC on Sept. 6, 2018 at 9:35 a.m. ET. A live webcast may be accessed by logging in at wsw.com/webcast/rrshq2….

We are excited to announce we have entered into a research collaboration with Cedars-Sinai to initiate an investigator-sponsored Phase 2 clinical study to further evaluate the efficacy and safety of SYN-010. View the press release at bit.ly/2Ni4yCt. #microbiome #IBS

Interim CEO & CFO, Steven Shallcross, presents a corporate overview today at 9:35am (ET) at the 20th Annual Rodman & Renshaw Global Investment Conference. Register for the live Webcast at bit.ly/2Q9aFYi

Seats were full as our VP of Non-Clinical Affairs, Dr. John Kokai-Kun, presents on SYN-004 (ribaxamase) preventing #CDI in patients being treated with beta-lactam #antibiotics at the 6th International #Cdiff Symposium in Bled, Slovenia. #ICDS2018 #microbiome

In a The Lancet Infectious Diseases article, SYNBiologics researchers report that, in a phase 2 trial, the oral beta-lactamase enzyme ribaxamase, when given to patients with LRTI in conjunction with IV ceftriaxone, reduced C diff incidence

Our rebrand to Theriva Biologics #TOVX marks the next phase in our journey to combat devastating cancers. At Theriva, we are advancing unique oncolytic viruses. Learn more: bit.ly/3MqWlIf

Our CEO and CFO, Steven Shallcross and General Director of EU Subsidiary, Manel Cascalló, PhD, were featured in an Endpoints News article to discuss the Company’s rebrand and Theriva’s path forward. Read the article here: bit.ly/3T5QRFG

Our COO, Frank Tufaro, PhD, will be presenting at the 14th International Oncolytic Virotherapy Conference in #Japan highlighting the encouraging biological activity of VCN-01 treatment in combination with #durvalumab. Learn more here bit.ly/3TtOZXq

Join us for a discussion hosted by Theriva Biologics, featuring Dr. Michael Aaron Morse, on the oncolytic virus landscape and Theriva Biologics’ encouraging data from novel oncolytic adenovirus (OV) platform. Register here: lifesci.events/TherivaReg

Tune in for our earnings call next Thursday, November 10 at 8:30 a.m. ET! We plan to discuss our third quarter financial results and business updates. You can access the live and archived webcast via our Investors page here: bit.ly/3Um1aFB

In case you missed it! We hosted a discussion featuring immunotherapy experts on the encouraging data from Theriva Biologics’ novel oncolytic adenovirus platform. Click here to watch: bit.ly/3DSYoRt

We reported Q3 operational and financial results during our earnings call. Highlights included advancements for our lead oncolytic virus product candidate, VCN-01 and preparations for the planned Phase 2 #PDAC trial. Learn more here: bit.ly/3A4tNQ8

During Theriva’s recent KOL event, immunotherapy experts discussed the challenges of treating patients with PDAC and unique oncolytic virus therapeutics, including VCN-01 that are advancing the field. Listen to the full discussion here: bit.ly/3DSYoRt

During Theriva’s KOL event, immunotherapy experts discussed the challenges of treating #PDAC patients. Listen to the full discussion to learn more about how oncolytic virus therapeutics, including VCN-01 can help patients: bit.ly/3DSYoRt #PancreaticCancer Awareness Month

We have dosed the first patient in our Phase 2b VIRAGE trial of VCN-01 in combination with chemotherapy as a first line therapy for patients with newly-diagnosed metastatic #PDAC. More on this #clinicaltrial and its progress here: bit.ly/3Hhm45d

We're presenting at ECCMID from April 15-18, 2023! Our poster presentation will showcase data from the ongoing Phase 1b/2a trial of SYN-004 (ribaxamase). Learn more and see our presentation details here: bit.ly/418s6wu